Monthly update of U.S. Food and Drug Administration (FDA) approvals impacting the workers' compensation industry. myMatrixx's report includes new drug and indication approvals, discontinuation and withdrawals, new dosages or formulations of existing products and newly available generics in the last 12 months.
Monthly Drug News
Axsome Therapeutics has announced the availability of Auvelity™ for the treatment of major depressive disorder in adults. Auvelity is a new combination drug containing dextromethorphan and bupropion that was approved by the FDA in August 2022. It was developed with the FDA Breakthrough Therapy designation for treatment of depression. In contrast to other antidepressants on the market, Auvelity acts more quickly – showing positive effects at one week.
Impact to Workers’ Comp
While depression is not the most common indication in workers’ compensation, it is still a noteworthy addition to the antidepressant class, which includes a variety of cost-effective alternatives already available. For any questions about the use of Auvelity, depression medications, and potential relatedness to a claim, please consult with your myMatrixx pharmacist.